BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. ✅
Go to Publication ✅
The Journal of international medical research (J Int Med Res ) Vol: 46 Issue 9 Pages: 3596-3604 Pub: 2018 Sep Epub: 2018 May 28 Authors Xia X , Chen J , Xia J , Wang B , Liu H , Yang L , Wang Y , Ling Z , |
|
|
Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. ✅
Go to Publication ✅
The Journal of international medical research (J Int Med Res ) Vol: 46 Issue 9 Pages: 3596-3604 Pub: 2018 Sep Epub: 2018 May 28 Authors Xia X , Chen J , Xia J , Wang B , Liu H , Yang L , Wang Y , Ling Z , |
|
|
Effect of Five Commercial Probiotic Formulations on Candida Albicans Growth: In Vitro Study. ✅
Go to Publication ✅
The Journal of clinical pediatric dentistry (J Clin Pediatr Dent ) Vol: 44 Issue 5 Pages: 315-322 Pub: 2020 Sep 1 Epub: Authors Hernández-Bautista LM , Márquez-Preciado R , Ortiz-Magdaleno M , Pozos-Guillén A , Aranda-Romo S , Sánchez-Vargas LO , |
|
|
Bifidobacteriumlongum subsp. infantis CECT7210 (B. infantis IM-1®) Displays In Vitro Activity against Some Intestinal Pathogens. ✅
Nutrients (Nutrients ) Vol: 12 Issue 11 Pages: Pub: 2020 Oct 24 Epub: 2020 Oct 24 Authors Ruiz L , Flórez AB , Sánchez B , Moreno-Muñoz JA , Rodriguez-Palmero M , Jiménez J , Gavilán CGLR , Gueimonde M , Ruas-Madiedo P , Margolles A , |
|
|
Bifidobacteriumlongum subsp. infantis CECT7210 (B. infantis IM-1®) Displays In Vitro Activity against Some Intestinal Pathogens. ✅
Nutrients (Nutrients ) Vol: 12 Issue 11 Pages: Pub: 2020 Oct 24 Epub: 2020 Oct 24 Authors Ruiz L , Flórez AB , Sánchez B , Moreno-Muñoz JA , Rodriguez-Palmero M , Jiménez J , Gavilán CGLR , Gueimonde M , Ruas-Madiedo P , Margolles A , |
|
|
[Bifidobacterium longum subsp. infantis CECT 7210 (B. infantis IM-1®) shows activity against intestinal pathogens]. ✅
Go to Publication ✅
Nutricion hospitalaria (Nutr Hosp ) Vol: 39 Issue Spec No3 Pages: 65-68 Pub: 2022 Sep 1 Epub: Authors Moreno-Muñoz JA , Martín-Palomas M , Jiménez López J , |
|
|
[Bifidobacterium longum subsp. infantis CECT 7210 (B. infantis IM-1®) shows activity against intestinal pathogens]. ✅
Go to Publication ✅
Nutricion hospitalaria (Nutr Hosp ) Vol: 39 Issue Spec No3 Pages: 65-68 Pub: 2022 Sep 1 Epub: Authors Moreno-Muñoz JA , Martín-Palomas M , Jiménez López J , |
|
|
Microencapsulated Bifidobacterium longum subsp. infantis ATCC 15697 favorably modulates gut microbiota and reduces circulating endotoxins in F344 rats. ✅
Go to Publication ✅
BioMed research international (Biomed Res Int ) Vol: 2014 Issue Pages: 602832 Pub: 2014 Epub: 2014 May 22 Authors Rodes L , Saha S , Tomaro-Duchesneau C , Prakash S , |
|
|
A Probiotic Bacterium with Activity against the Most Frequent Bacteria and Viruses Causing Pediatric Diarrhea: Bifidobacterium longum subsp. infantis CECT 7210 (B. infantis IM1(®)). ✅
Go to Publication ✅
Microorganisms (Microorganisms ) Vol: 12 Issue 6 Pages: Pub: 2024 Jun 11 Epub: 2024 Jun 11 Authors Moreno-Muñoz JA , Ojeda JD , López JJ , |
|
|
A Probiotic Bacterium with Activity against the Most Frequent Bacteria and Viruses Causing Pediatric Diarrhea: Bifidobacterium longum subsp. infantis CECT 7210 (B. infantis IM1(®)). ✅
Go to Publication ✅
Microorganisms (Microorganisms ) Vol: 12 Issue 6 Pages: Pub: 2024 Jun 11 Epub: 2024 Jun 11 Authors Moreno-Muñoz JA , Ojeda JD , López JJ , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
